The potentially life-threatening infection streptococcal endo-docarditis can be cured by a single injection of Hoffmann-La Roche's cephalosporin antibiotic Rocephin (ceftriaxone), according to a multicenter study carried out in France, Belgium and Switzerland. The infection generally arises after patients undergo surgery.
The trial involved 59 patients, who were followed up for periods ranging from four months to five years. An injection of 2g ceftriaxone daily for four weeks resulted in a cure without adverse reactions in 71% of patients. The treatment was also associated with a reduced need for catheterization, and 39% of patients were discharged from the hospital less than two weeks after admission. The researchers therefore suggest that ceftriaxone treatment could be given on an outpatient basis, thus avoiding costly hospitalization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze